BioMarin PharmaceuticalsBMRN
Recorded

BioMarin Pharmaceuticals Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right, great. Thanks very much. Happy to be moderating a chat here with the BioMarin management team. I think Brian, CFO, which I'm sure everybody knows, is going to make some opening remarks, and then I think we're going to use this as an opportunity to spend some time with Greg and talk more about the pipeline that BioMarin's building out. Please take it away, Brian.

Brian MuellerCFO

Thank you. Thanks, Paul. Appreciate it.

Brian MuellerCFO

Thanks for having us. Good afternoon, everyone. Yes, some opening remarks. We're just a week out of our Q3 report, and lots of strong progress and results this year. We are executing on one of the core elements of our strategy, which is using our financial strength to fund future innovation. Very strong Q3 with revenue growth of 32%. We reached $1 billion of total revenue for the first time in the company history. A lot of that was driven by our metabolics conditions business unit with 44% growth. We're also growing earnings per share and profitability. One note there is that we have had two acquisitions in the third quarter, which are driving some level of in-process research and development expense.

Brian MuellerCFO

A lot of our growth is being driven by the recent acquisition of Amicus Therapeutics that brought two high-growth rare disease assets into our metabolic conditions portfolio. That is GALAFOLD for Fabry disease and POMBILITI and OPFOLDA for Pompe disease. These patients, we're growing patients at a double-digit rate. For GALAFOLD, we shared in one specific market, we grew patients at 20% in the third quarter year-over-year. POMBILITI and OPFOLDA is earlier in its growth cycle, and revenues grew almost 60%. Amicus is also more than just a revenue growth story. We think the deal has the potential to be highly accretive to the bottom line. We shared recently that we've identified roughly 50% of operating expense synergies on a non-GAAP basis when looking at the base Amicus operating expenses.

Brian MuellerCFO

We think those synergies of roughly $220 million will be fully realized for a full year in 2028. The integration will be mostly completed by the middle of next year, and we think that the Amicus business can be run at a roughly 60% operating margin by the end of the decade, which then gets to a healthy inflection on what was already the growing profitability profile of historical BioMarin. I think the last thing I'll mention, and this is where really great to have Greg with us here today, is we are delivering on our objective of rebuilding our pipeline. We've added four new assets to our pipeline this year. The first is BMN 450, most recently announced. This is the first potential subcutaneous injection of a Fabry disease therapy, enzyme replacement therapy. Next is BMN 440. This is the first potential oral therapy for hypophosphatasia, which is a significant commercial opportunity.

Brian MuellerCFO

Next is BMN 430, which is a preclinical program for a actually recently discovered disease area, disease in ReNU syndrome. Lastly is BMN 820, which came to BioMarin through the Amicus acquisition. This is a partnered asset. We have U.S. rights. It is for FSGS, the rare kidney condition. We are delivering on growth, innovation, and our value commitment objectives, and happy to go where you would like, Paul.

Paul MatteisAnalyst

Thanks. Okay, thanks. I will just take the pipeline in a very slightly different order because I wanted to first talk about hypophosphatasia.

Paul MatteisAnalyst

That is an indication in a market I have been interested in from covering Alexion, and maybe I was wondering what you could talk about the Alesta program, the thesis there, and sort of the parts of the market that it could serve relative to Strensiq and the Alexion AZ one.

Greg FribergChief Research and Development Officer

Yeah. Thanks for the question, Paul. We are really excited about it. We call it BMN 440. It is a small molecule. It targets ENPP1. In that regard, if you think about hypophosphatasia, this is a condition where patients are missing an enzyme. They are missing alkaline phosphatase, and the result of that is they have an increase in their serum, in their bodies, in inorganic pyrophosphate. That increase leads to decreased bone mineralization and a variety of other problems through the patient's life. The available enzyme replacement therapies, we mentioned a couple of them just now, are bone-targeting agents that try to, again, metabolize that pyrophosphate to downstream products. What BMN 440 is a small molecule that is trying to inhibit its production. Think of it as a substrate reduction therapy, not dissimilar to Gaucher.

Paul MatteisAnalyst

If you inhibit its production, does that ultimately shut it off and the excess that is around is cleared by the body?

Greg FribergChief Research and Development Officer

Is that the thought? The thought is that you're actually decreasing the production of it altogether.

Greg FribergChief Research and Development Officer

Okay. If you bring it down to a normal level, you can have the same benefits of improving bone mineralization.

Greg FribergChief Research and Development Officer

But unlike the enzyme replacements that are engineered to be bone-seeking, a small molecule has the opportunity as well to reach compartments like the muscle and the joints, which particularly for certain phenotypes in the disease, that's where a majority of their problems come from. It's not necessarily rickets or soft bones that they're complaining of. It's more pain, it's more joint problems, it's sleep deprivation. The hope is here that we can look at each of these sub-segments appropriately, deploy this molecule, and not just deliver an oral, more convenient therapy, but also one that might target these conditions in a way that treats the symptoms that are really bothering many of these patients.

Paul MatteisAnalyst

Okay, got it. There's kind of a wide range of phenotypic severity within this. I guess I don't want to say if it's like a family of diseases, it's the same condition, but there's the infantile onset, there's the adult. How do you think about positioning this?

Greg FribergChief Research and Development Officer

Yeah, I think what we're learning, and some great work done again here by Alexion AZ, is that you need to think of these populations as different opportunities, different needs. Infants, of course, which we're not talking about for BMN 440, have mortality as a major problem.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day